Hormone Therapy for Prostate Cancer Rensselaer NY

Hormone therapy to treat advanced prostate cancer can increase the risk of heart disease, but some types of hormone therapy appear to be safer than others, new research has found. The study included 30,642 Swedish men with either locally advanced prostate cancer or prostate cancer that had spread (metastatic cancer), who had received hormone therapy as primary treatment for their cancer.

Local Companies

MARK WHITE, MD
(518) 262-3341
23 Hackett Boulevard
Albany, NY
DAVID ZORNOW, MD
(518) 438-1019
319 S Manning Boulevard
Albany, NY
GERALD KOTZIN, MD
(518) 439-7161
17 Quincy Road
Glenmont, NY
Oscar Foz Almonte, MD
518-272-1333
267 Hoosick St
Troy, NY
Eric I Engelmyer, MD
518-374-3341
2200 Rosa Rd
Schenectady, NY
Zachary Hobart Passaretti
(518) 434-1283
63 Shaker Rd
Albany, NY
BADAR MIAN, MD
(518) 262-3341
23 Hackett Boulevard
Albany, NY
MARTIN ENGELSTEIN, MD
(518) 489-7494
4 Executive Park
Albany, NY
WILLIAM TUONG, MD
(518) 272-1333
267 Hoosick Street
Troy, NY
Ronald Paul Kaufman Jr, MD
518-262-3341
23-25 Hackett Blvd MC208
Albany, NY
Data Provided by:
    

Provided By:

TUESDAY, Sept. 22 (HealthDay News) -- Hormone therapy to treat advanced prostate cancer can increase the risk of heart disease, but some types of hormone therapy appear to be safer than others, new research has found.

The study included 30,642 Swedish men with either locally advanced prostate cancer or prostate cancer that had spread (metastatic cancer), who had received hormone therapy as primary treatment for their cancer.

The study findings were scheduled to be presented Tuesday at the European Cancer Organization meeting in Berlin.

In a news release from the European Cancer Organization, the researchers described the types of hormone therapy used: removal of the testicles to eliminate the main source of testosterone production; injections of gonadotropin-releasing hormone agonists to reduce testosterone production by the testicles; and anti-androgen pills that block testosterone from attaching to prostate cells. Most of the patients received one treatment, but 38 percent were given two types of drugs, the study authors noted.

The men were followed for an average of three years and monitored for ischemic heart disease, heart attacks, arrhythmia, and heart failure.

"We found that prostate cancer patients treated with hormone therapy had an elevated risk of developing all of the individual types of heart problems and that they were more likely than normal to die from those causes," study lead author Mieke Van Hemelrijck, a cancer epidemiologist at King's College in London, England, said in the news release.

Specifically, hormone therapy was associated with a 24 percent increased risk of heart attack, a 19 percent increased risk of arrhythmia, a 31 percent increased risk of ischemic heart disease, and a 26 percent increased risk of heart failure, the researchers found. The increased risk of heart disease began a few months after the men began hormone therapy.

The study also found that hormone therapy was associated with a 28 percent increased risk of fatal heart attack, a 21 percent increased risk of dying from heart disease, a 26 percent increased risk of death from heart failure, and a 5 percent increased risk of fatal arrhythmia.

"In a more detailed analysis by type of hormone therapy, the lowest increase in risk for ischemic heart disease, heart attack and heart failure was seen in the group taking anti-androgen therapy, and we saw no increase in risk of death from heart disease in this group. Patients on gonadotropin-releasing hormone agonist therapy had the highest risk of these problems," Van Hemelrijck said.

The findings suggest that physicians should consider heart-related side effects when prescribing hormone therapy for prostate cancer patients and may want to refer patients to a cardiologist before the start of hormone therapy, the researchers stated.

More information

The American Urological Association Foundation has more about hormone therapy for prostate cancer.

SOURCE: European Cancer Organization, news release, Sept. 22, 2009

Copyright © 2009 ScoutNews, LLC. All rights reserved.

Read Article at HealthDay.com

Related Articles
- Diagnosis of Prostate Cancer Rensselaer NY
Mass screening for prostate cancer with a test for prostate-specific antigen (PSA) has led to mass over-diagnosis and over-treatment, a new study contends. Since the PSA screening test came into use in 1986, federal government data show that the number of prostate cancer cases in the United States has risen substantially, said the report in the Aug. 31 online issue of the Journal of the National Cancer Institute.
- Hormone Therapy for Early Prostate Cancer Rensselaer NY
- Delayed Prostate Cancer Therapy Rensselaer NY
- Menopausal Hormone Therapy Rensselaer NY
- Exercise for Prostate Cancer Rensselaer NY
- Hormone Therapy for Breast Cancer Rensselaer NY
- Open Prostatectomy Versus Laparoscopic Procedure Rensselaer NY
- Hormone Therapy for Lung Cancer Rensselaer NY
- Head and Neck Cancer Treatment Rensselaer NY
- Hormone Therapy Rensselaer NY